We read with interest Mitsiades et al's recent paper 1 purporting to define the intracellular factors regulating tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) activity in myeloma cells. They demonstrated quite clearly the crucial role for procaspase-8 activation in initiating TRAIL-induced apoptosis and the clear correlation between the efficiency of procaspase-8 activation and the degree of TRAIL-induced apoptosis. Furthermore, they were able to demonstrate that maneuvers capable of inhibiting antiapoptotic proteins or artificially elevating the levels of intracellular procaspase-8 enhanced the apoptosis-inducing capability of TRAIL. This preliminary data demonstrating the "sensitization" of previously TRAIL-resistant myeloma cells with novel agents are very interesting and, if it can be confirmed that these strategies do not also sensitize nonmalignant cells, may well provide a rationale for early-phase clinical trials.
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Of concern, however, is the claim that the degree of TRAIL resistance of the cell lines studied was associated with a low procaspase-8/cFLIP (FLICE inhibitory protein) ratio. No data are actually presented to support this assertion. Scrutiny of the data that are presented shows that there is no obvious correlation between the physiologic levels of cFLIP and/or procaspase-8 and the degree of TRAIL-induced apoptosis for the cell lines studied. This is clearly exemplified by the "sensitive" cell lines MM1S and RPMI showing quite different immunoblot findings, with high procaspase-8/low cFLIP ratios and low procaspase-8/high cFLIP ratios, respectively. Our own data from 5 authentic myeloma cell lines confirm the crucial relationship between the efficiency of procaspase-8 activation and TRAIL-induced apoptosis ( Figure 1 ) and also show the lack of correlation between the physiologic procaspase-8/cFLIP levels and TRAIL-induced apoptosis ( Figure 2 ).
There are 4 known surface receptors for TRAIL, 2 of which (TRAIL-R1 and TRAIL-R2) appear to be capable of inducing apoptosis upon binding of TRAIL. 2 Our understanding of TRAIL-TRAIL receptor interactions beyond this is limited. But the earlier belief that the 2 "decoy" TRAIL receptors (TRAIL-R3 and TRAIL-R4) lacking intracellular death domains somehow protect cells from TRAIL has been shown by our group and others to be incorrect. [3] [4] [5] For TRAIL to be exploited maximally as an antitumor agent, how it works must be more thoroughly understood, particularly the exact roles of the known TRAIL receptors. Acceptance of the perhaps premature assertion that myeloma-cell TRAIL sensitivity is regulated by physiologic levels of procaspase-8 and/or cFLIP will do little to improve this lack of understanding. [1] [2] [3] We have attempted to dissect out differences in our respective study approaches that may have led to discordant results. While Spencer et al's letter does not provide the methodology for the included experiments nor list the antibodies used to determine procaspase-8 and FLIP protein expression, there are concerns raised by the interpretation of these data in view of the cell lines and methodology previously used by these investigators. One key concern is the suboptimal level of TRAIL-induced tumor cell death noted for the RPMI 8226/S myeloma cell line in their previous study, 4 as well as outright resistance to TRAIL for both U266 and NCI H929 myeloma cells per their letter. But in deference to their own studies, Spencer and colleagues acknowledge that NCI H929 myeloma cells are TRAIL-sensitive in their Leukemia article, 4 while describing these cells as TRAIL-resistant in their letter. One likely explanation for this discrepancy is that Spencer et al measure TRAIL-induced apoptosis by annexin V only after one hour of TRAIL treatment. This likely is a very early time point to determine the full extent of TRAIL-induced apoptosis, because as shown in our previous studies, 5 myeloma cells become annexin V-positive after 4 to 6 hours of TRAIL treatment. This likely explains why in their letter Spencer et al have incorrectly classified the NCI H929 and U266 cell lines as TRAIL-resistant. In our hands, as well as those of many other investigators, all of the above cell lines have exhibited marked sensitivity to TRAIL, [6] [7] [8] [9] including the NCI H929 cell line, which exhibited an inhibitory concentration 50% (IC50) of below 100 ng/mL and showed TRAIL sensitivity similar to the TRAIL-sensitive LP-1 and OPM-2 myeloma cells reported by Spencer et al in Figure 1 of their letter. One possible explanation for these discordant findings is the technique used to determine induction of apoptosis by TRAIL. The authors curiously report in Leukemia that they first undertook to remove dead cells following TRAIL treatment by density gradient centrifugation over Lymphoprep (Nycomed Pharma, Oslo, Norway) before establishing the percentage of cells that underwent apoptosis, thus potentially underestimating cell death. The rationale for taking this step remains unclear and hampers the valid interpretation of these studies since appropriately establishing TRAIL sensitivity is a prerequisite to discerning intracellular regulatory pathways.
It does remain unclear, as suggested by Spencer et al, whether the use of Epstein-Barr virus (EBV) genome containing cell lines is a confounding factor in these and other studies since modulation of both caspase-8 and FLIP have been reported as a potential mechanism of EBV tumorigenesis in Burkitt lymphoma. 10 But a certain subset (or subsets) of multiple myeloma (MM) may be EBV-related in view of reports that have demonstrated EBV genomic presence in freshly obtained MM patient cells. [10] [11] [12] [13] Interestingly, this subset may include those patients with CD20 ϩ disease since EBV nuclear antigen 3C (EBNA-3C) modulates the PU.1 transcription factor 14 that is normally down-regulated in plasma cells and is responsible, along with the PU.1 interacting partner (Pip), for CD20 expression (reviewed in Treon et al 15 ). This point is especially worth mentioning since the cell lines in our study that were moderately or highly TRAIL resistant were CD20 ϩ and have been reported to be EBV ϩ as well. To the editor:
Hematopoietic progenitor cell harvest and functionality in Fanconi anemia patients
Recently, Croop et al 1 reported the feasibility of mobilizing and collecting peripheral blood CD34 ϩ progenitor cells from patients with Fanconi anemia. The authors performed successful apheresis collection in 6 of 8 patients. They showed that prolonged granulocyte colony-stimulating factor (G-CSF) administration (median 10 Ϯ 4 d) and days of apheresis (4 Ϯ 3 d; range, 2-8 d) were required and that such procedure led to significant adverse events. This study supported evidence that patients with Fanconi anemia can be mobilized, but the authors did not answer the question of whether these hematopoietic progenitors were functional and could efficiently participate to autologous reconstitution after infusion. In this scope, data concerning granulocyte-macrophage colonyforming unit (GM-CFU) assays would have been of great interest. We would like to report our experience with G-CSF-mobilized peripheral blood CD34 ϩ cells (n ϭ 4) or bone marrow (BM) harvest (n ϭ 2) in patients with Fanconi anemia, using a standard collection method. At the time of harvest, none of the patients had criteria of severe aplastic anemia (defined by hemoglobin level below 80 g/L [8 g/dL], absolute neutrophil count below 0.5 ϫ 10 9 / L, and platelet count below 20 ϫ 10 9 /L) and were transfusion independent ( Table 1 ). All 4 mobilized patients, with a mean age of 17.3 y (range, 4-31 y), received G-CSF at the daily dose of 10 g/kg for 5 days. Two of them failed to mobilize, while the other 2 underwent apheresis with a number of initial peripheral blood CD34 ϩ counts of 9.4/L and 9.8/L. Within 2 days of apheresis, the numbers of total nucleated cells collected in these 2 patients were 84.86 ϫ 10 9 /kg and 90.14 ϫ 10 9 /kg and the numbers of CD34 ϩ cells were 1.53 ϫ 10 6 /kg and 0.9 ϫ 10 6 /kg. GM-CFU assays were performed by seeding 1 ϫ 10 3 CD34 ϩ cells in a conventional methylcellulose culture assay in order to determine myeloid progenitors cell growth. Interestingly, CD34 ϩ progenitor cells failed to generate GM-CFU colonies with numbers of 0.42 ϫ 10 4 or 1 ϫ 10 4 GM-CFU/kg patient weight, thus suggesting a low clonogenic capacity of CD34 ϩ cells even in patients without severe bone marrow failure. We determined that CD34 ϩ cells from Fanconi anemia patients have 5 to 12 times lower levels of GM-CFU/kg, as compared with 72 patients with hematologic malignancies for whom apheresis, performed with the same standard conditions, led to a median of 1.1 ϫ 10 6 CD34 ϩ /kg (median GM-CFU/kg, 5.1 ϫ 10 4 ). The same pattern of dramatic decrease in CD34 ϩ cells (0.03 ϫ 10 6 /kg and 0.12 ϫ 10 6 /kg) and GM-CFU (0 ϫ 10 4 /kg) was observed in both patients that underwent BM harvest. These results contrast with a relatively normal blood count that cannot be predictive of CD34 cell recovery or functionality.
Similar to a murine model of FANCC disruption clearly demonstrating a reduced repopulating ability of hematopoietic stem cells, 2 
